BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025
BCDA(NASDAQ:BCDA) SUNNYVALE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- - BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that BioCardia’s President and CEO, Peter Altman, PhD., will present a corporate update, including recent progress toward milestones, at the H. C. Wainwright 27th Annual Global Investment Conference at the Lotte Palace Hotel in New York City.
BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results
BCDASUNNYVALE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2025 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session.
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025
BCDASUNNYVALE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the three months ended June 30, 2025 by conference call on Monday, August 11, 2025 at 4:30 PM ET. Following management’s formal remarks, there will be a question-and-answer session.
BioCardia Q1 EPS $(0.59) Misses $(0.39) Estimate
BCDABioCardia Initiates Patient Enrollment At University Of Wisconsin At Madison For Ongoing CardiAMP HF II Pivotal Study
BCDA12 Health Care Stocks Moving In Friday's After-Market Session
BCDABioCardia Doses First Patient In Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial Of Cell Therapy For Treatment Of Heart Failure
BCDADSMB Recommends That Study On Biocardia's CardiALLO-HF Trial Proceeds As Designed Based On 30-day Data Safety Assessment Of Participants Treated In Low Dosage Group
BCDABioCardia Initiates Enrolling Patients With Ischemic Heart Failure At Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study
BCDABiocardia Phase 3 CardiAMP-HF Trial Of Novel Cardiac Cell Therapy For Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, And Improved Quality Of Life At 2-Years
BCDABioCardia FY 2024 GAAP EPS $(2.90) Beats $(3.11) Estimate, Sales $58.00K Miss $91.50K Estimate
BCDABioCardia Announces That The Japan Patent Office Has Granted Japanese Patent No. 7641330 Titled Radial And Transendocardial Delivery Catheter
BCDABioCardia Announces Completion Of Source Data Verification And Freezing Of Primary Outcomes Data In Phase 3 CardiAMP HF Study
BCDABioCardia Completes Low Dose Cohort Enrollment For CardiALLO Phase I/II Clinical Trial Of BCDA-03 Allogeneic Mesenchymal Stem Cells
BCDAHC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target
BCDABioCardia Intends To Effect Reverse Stock Split Of Its Common Stock At Ratio Of 1 Post-Split Share For Every 15 Pre-Split Shares
BCDABioCardia Announces CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data To Be Presented At Heart Failure Society Of America Annual Meeting
BCDA